Dr. Fischer is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2121 Santa Monica Blvd
Santa Monica, CA 90404Phone+1 310-829-8781Fax+1 310-582-7185
Summary
- Trevan Fischer, MD, is an Assistant Professor of Surgical Oncology at Saint John's Cancer Institute at Providence Saint John's Health Center. He is the Assistant Program Director of the Donald L. Morton, MD Complex Surgical Oncology Fellowship program. He came to JWCI in 2015 as a Surgical Oncology Fellow and transitioned to faculty after graduation. He is board-certified in General Surgery and Complex General Surgical Oncology. He completed his General Surgery residency at the University of Florida. He attended the University of Oklahoma for medical school. Dr. Fischer's clinical interest are melanoma and cutaneous oncology, breast oncology and soft tissue sarcomas. He also believes in advancing the science of minimally invasive and innovative surgery. Dr. Fischer was drawn to surgical oncology due to the multidisciplinary team approach to caring for patients. He feels this team approach has led to many improvements in the quality of care that cancer patients receive.
Education & Training
- Saint John’s Cancer Institute/Providence Saint John’s Health CenterFellowship, Complex General Surgical Oncology, 2017
- University of FloridaResidency, Surgery, 2008 - 2015
- University of Oklahoma College of MedicineClass of 2008
Certifications & Licensure
- CA State Medical License 2015 - 2025
- American Board of Surgery Surgery
- American Board of Surgery Complex General Surgical Oncology
Awards, Honors, & Recognition
- Administrative Chief Fellow John Wayne Cancer Insititute, 2016-2017
- T32 Training Grant University of Florida, 2010-2012
Clinical Trials
- Recombinant Human Arginase 1 (rhArg1) in Patients With Advanced Arginine Auxotrophic Solid Tumors Start of enrollment: 2014 Nov 01
- Phase IIB TL + YCWP + DC in Melanoma Start of enrollment: 2015 Jan 01
- Intratumoral CAVATAK (CVA21) and Ipilimumab in Patients With Advanced Melanoma (VLA-013 MITCI) Start of enrollment: 2015 May 05
- Join now to see all
Publications & Presentations
PubMed
- 64 citationsNeoadjuvant Chemotherapy Improves Survival in Patients with Clinical T4b Colon CancerAhmed Dehal, Amanda N Graff-Baker, Brooke Vuong, Trevan D Fischer, Samuel J. Klempner
Journal of Gastrointestinal Surgery. 2018-02-01 - 581 citationsMultiple early factors anticipate post-acute COVID-19 sequelae.Yapeng Su, Dan Yuan, Daniel G Chen, Rachel H Ng, Kai Wang
Cell. 2022-03-03 - 9 citationsInaccurate pretreatment staging can impact survival in early stage esophageal adenocarcinoma.Anthony J Scholer, Abhineet Uppal, Shu Ching Chang, Debopriya Ghosh, Mary Kledzik
Journal of Surgical Oncology. 2020-07-06
Press Mentions
- 5 Skin Cancer-Care Tools You Should Look Out ForApril 24th, 2023
- COVID-19: What You Need to Know About Hand SanitizerMarch 20th, 2020
- That Hand Sanitizer You’ve Stocked up May Do More Harm Than GoodMarch 13th, 2020
- Join now to see all
Professional Memberships
- Member
- Member
External Links
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: